idea-002 · desirability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the veterinary surgeon standing over a degloved limb, the technician who has to make the dressing stick to fur, and the owner who pays cash and takes the animal home with a pump attached to it.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-002.md — the number is the claim's position in its ## Claims list, the tag is copied from it and never adjusted here. A [no claim] marker means nothing in the file speaks to the condition at all. See docs/deck-spec.md.
What changed since the 2026-08-24 build: the research lane read eight studies at abstract depth (claims 32-39), and they change the clinical picture from "thin and negative" to "genuinely mixed" — including the first favourable canine comparative result in the file. Every one is unconfirmed, and for a reason worth carrying: a scan result can locate a paper but can never appraise it, so these are "attempted and structurally unverifiable, not unattempted". Rebuilt from the file, not patched.
Would have to be true: There would have to be tens of thousands of canine and equine distal-limb wounds a year severe enough that a surgeon reaches for something beyond standard bandaging — and the surgeon would have to be dissatisfied with what they reach for now.
Where it stands: The caseload is still a Generator range the market connector reports as unverifiable [claim 13: unconfirmed]. What the surgeon reaches for today is better documented than it was: the human single-use device is used off-label in published canine and equine work [claim 8: verified], [claim 10: verified] — both verified (bibliographic existence only), meaning the records exist and nothing about their findings is established by that tag — and the research lane has now read the case series behind them, which describe real clinical use in this species at this site [claim 35: unconfirmed], [claim 36: unconfirmed], [claim 38: unconfirmed].
What would settle it: ACVS/ACVIM abstract books and veterinary teaching-hospital caseload data, human-attached — no connector here reaches veterinary caseload. A distributor's unit volumes for existing human NPWT sold into veterinary channels would be a sharper proxy.
If it's false: The addressable caseload is a specialty-referral sliver, and the TAM components [claim 13: unconfirmed], [claim 15: unconfirmed] are counting a market that does not concentrate anywhere a sales motion can reach.
Would have to be true: A technician would have to get an airtight seal on a furred, conical, moving limb — reliably, in a normal practice, without tricks — and then the owner would have to keep the assembly on the animal at home for days.
Where it stands: Both remain unbacked [claim 23: unconfirmed], [claim 22: unconfirmed], and this is still where the literature speaks most directly against the product. The AJVR pilot reports that a complete seal required adhesive spray, that vacuum maintenance "lessened over time", and that the device "is feasible but problematic in maintaining a vacuum, requiring frequent revisions of the dressing" [claim 9: unconfirmed]. Two new findings sharpen the tolerance half rather than the seal half. In humans, 20% of NPWT patients ceased therapy prematurely at their own request, citing experienced limitations in daily activities [claim 32: unconfirmed] — a species that can be asked, reasoning about a burden a dog cannot consent to. And in the 42-horse series, 26% were discharged before NPWT was considered ideally complete [claim 36: unconfirmed]. The candidate's proposed moat — a fur-compatible drape and limb-conforming interface [claim 16: unconfirmed] — is aimed precisely at the seal failure, which remains the strongest thing on this deck in the idea's favour: the published failure mode lands on the exact component the product proposes to engineer.
What would settle it: Seal-retention testing on limb models through a real motion cycle, then a prospective case series at a teaching hospital with application handled by ordinary technicians rather than the study's authors.
If it's false: The product fails at the hands of the person applying it, which no clinical benefit can rescue — and the failure will be read by the profession as the therapy failing.
Would have to be true: The owner would have to pay cash, the practice would have to stock the unit, and the surgeon would have to prefer a purpose-built veterinary device over the human unit they can already buy.
Where it stands: Unmoved by the last week's work, and it is the only slide on this deck that the research lane did not touch. The last of the three is the candidate's own flagged assumption, stated as an assumption rather than a fact: the idea depends on veterinary surgeons choosing a purpose-built unit over continuing to buy human PICO units off-label at similar or lower cost, with no connector for purchasing preference and no primary research behind it [claim 19: unconfirmed]. Owner willingness to pay is on record and unchecked [claim 21: unconfirmed], and the payment structure is unforgiving: there is no third-party payer code of any kind [claim 11: unconfirmed], and pet insurance is claimed to sit under 5% of owned dogs [claim 12: unconfirmed]. Whether practices will dispense for home use at all is unbacked [claim 24: unconfirmed].
What would settle it: Interviews with ACVS-affiliated surgeons on the off-label-versus- purpose-built trade; practice-manager interviews on stocking and dispensing; published pet insurance penetration from an industry association, human-attached.
If it's false: The product loses to a human device already in the building — the cheapest competitor to beat and the hardest, because it needs no decision from anyone.
Would have to be true: The owner's out-of-pocket cost would have to be justified by a benefit the surgeon can describe honestly — on top of a surgical bill already being paid in cash.
Where it stands: The price is a Generator estimate [claim 14: unconfirmed] with no payer to absorb it [claim 11: unconfirmed]. The honesty problem has become genuinely two-sided since the last build, and the geography of the evidence is what matters. Against: at this candidate's exact anatomical site, a controlled 10-horse experiment on the dorsomedial metacarpus found limited added value versus calcium alginate, with NPWT giving significantly less wound retraction in noncontaminated wounds [claim 20: unconfirmed]; and a 2026 equine commentary reports isolated PICO-system NPWT insufficient to stimulate healing in a small series, with no reduction in wound size [claim 39: unconfirmed]. For: a retrospective matched-pairs comparison of 50 dogs found significantly fewer complications (p=0.008) and significantly less sepsis (p=0.016) than foam dressing [claim 34: unconfirmed], and in humans a systematic review of 29 studies (n=5,614) found single-use canister-free NPWT reduced surgical-site infection, dehiscence, seroma and necrosis versus conventional dressings [claim 33: unconfirmed]. The negative canine pilot is worth placing precisely rather than citing loosely: it is an n=5 Beagle study on surgically created hemithorax wounds [claim 9: unconfirmed] — not the distal limb this product is for. All of these are unconfirmed in the strict sense used here: the connector establishes the records exist [claim 8: verified] but a scan result can never appraise a finding.
What would settle it: A human reading the full texts for design, power, site and endpoint — the AJVR paper, the EVJ paper, and the 50-dog VCOT comparison, which is the one that would most change the picture if it holds up. Nothing in this repo can do it.
If it's false: The surgeon is asking an owner to pay for an adjunct whose published record at this site is unfavourable, which is a conversation that ends sales.
Would have to be true: ACVS opinion leaders would have to see a result in this species, at this site, in this format — because that is exactly where the existing literature is weakest.
Where it stands: Better than the last build reported, and still not sufficient. The favourable veterinary record is now four studies deep but almost entirely uncontrolled: 7 dogs with 100% graft survival after distal-extremity free skin grafts [claim 35: unconfirmed], 8 dogs with 7 of 8 achieving excellent graft take [claim 38: unconfirmed], 42 horses with 69% satisfactory healing at discharge [claim 36: unconfirmed], and one genuine comparative result in 50 dogs [claim 34: unconfirmed]. Against it sit the two site-specific comparative papers [claim 20: unconfirmed], [claim 39: unconfirmed]. The bibliographic existence of this literature is what the file verifies [claim 8: verified], [claim 10: verified] — not its findings. The candidate's capital plan already anticipates the gap: it budgets one or two prospective clinical case series at veterinary teaching hospitals [claim 18: unconfirmed]. Evidence is the go-to-market here, not a regulatory obligation — nothing forces it [claim 2: verified].
What would settle it: A prospective controlled series in canine distal-limb and equine distal-limb wounds, with the interface this product actually proposes.
If it's false: There is no clinical story to tell, and the sale depends entirely on convenience versus a human device that is already convenient.
Would have to be true: A dozen conversations at referral practices would have to return a consistent account: real caseload, real dissatisfaction with the current seal, and willingness to pay for a purpose-built unit.
Where it stands: No primary research sits behind this candidate, and the file is explicit that practitioner purchasing preference has no connector [claim 19: unconfirmed]. There is also a structural blindness worth restating so no one misreads a clean scan: openFDA holds no records for animal-only devices, so a none from clearances or recalls is coverage absence, not competitive absence. The one place that blindness does not apply is instructive: a recall scan on the human product code found that 51% (19 of 37) of recalls for canistered NPWT pumps name a canister, dressing-connector or tubing defect [claim 37: unconfirmed] — evidence about the failure mode this product's canister-free form removes, drawn from the human database precisely because the veterinary one does not exist.
What would settle it: The practice visits, plus distributor catalogues (Covetrus, Patterson Vet, MWI) for what is actually marketed to these buyers today.
If it's false: The idea is a human device retargeted on paper, and the veterinary user was inferred from the literature rather than asked.
Every condition above with nothing verified behind it.
verified, which is why eight new studies moved the picture without moving a single tag.
The four verified claims in this file are still two regulatory facts and two statements that records exist. Not one of them says the therapy works in this species. What has changed is that the unconfirmed evidence no longer points one way: there is now a favourable canine comparative result [claim 34: unconfirmed] sitting against an unfavourable equine one at the target site [claim 20: unconfirmed], and reconciling them is a reading task, not a connector task.
If only one thing from this chair could be checked: whether a technician can get and keep a seal on a furred distal limb in ordinary practice conditions [claim 23: unconfirmed].
It survives the week's new evidence unchanged, and the evidence arguably strengthens it. It is the product's entire reason to exist as something other than a repackaged human unit [claim 19: unconfirmed]; it is the mechanism by which the published canine pilot failed [claim 9: unconfirmed]; it is the only moat the file names [claim 16: unconfirmed]; and the recall data now says the same thing from the human side, where half of all canistered-NPWT recalls name a connector, tubing or canister defect [claim 37: unconfirmed]. It is also answerable on limb models this quarter, without an animal, a regulator or a payer — which is unusual for a condition this decisive.
Naming it is not a recommendation, a gate, or a kill.